Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens

被引：42

作者：

Burman, William J. ^{[1
]}

Cotton, Mark F. ^{[2
]}

Gibb, Diana M. ^{[3
]}

Walker, A. Sarah ^{[3
]}

Vernon, Andrew A. ^{[4
]}

Donald, Peter R. ^{[2
]}

机构：

[1] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA

[2] Univ Stellenbosch, Fac Hlth Sci, Dept Pediat & Child Hlth, ZA-7505 Tygerberg, Western Cape, South Africa

[3] MRC, Clin Trials Unit, London, England

[4] Ctr Dis Control & Prevent, Atlanta, GA USA

来源：

PLOS MEDICINE | 2008年 / 5卷 / 08期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1371/journal.pmed.0050176

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We are on the threshold of revolutionary improvements in the treatment of tuberculosis. Within five to ten years, it is likely that highly effective three-month regimens will be available to treat both active and latent drug-susceptible tuberculosis. New drug classes that have the potential to dramatically improve the treatment of multidrug-resistant tuberculosis are entering clinical trials. Children have the same right as adults to benefit from research with these new treatments. By making a deliberate choice to avoid the path of least resistance, we can ensure that both adults and children benefit from these advances in tuberculosis treatment.

引用

页码：1168 / 1172

页数：5

共 41 条

[1] [Anonymous], 1948, BMJ, V2, P769, DOI [10.1136/bmj.2.4582.769, DOI 10.1136/BMJ.2.4582.769]
[2] Cost-effectiveness of highly active antiretroviral therapy in South Africa
Badri, M
Maartens, G
Mandalia, S
Bekker, LG
Penrod, JR
Platt, RW
Wood, R
Beck, EJ
[J]. PLOS MEDICINE, 2006, 3 (01) : 48 - 56
[3] World antimalarial resistance network (WARN) IV: Clinical pharmacology
Barnes, Karen I.
Lindegardh, Niklas
Ogundahunsi, Olumide
Olliaro, Piero
Plowe, Christopher V.
Randrianarivelojosia, Milijaona
Gbotosho, Grace O.
Watkins, William M.
Sibley, Carol H.
White, Nicholas J.
[J]. MALARIA JOURNAL, 2007, 6 (1)
[4] Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia
Bolton-Moore, Carolyn
Mubiana-Mbewe, Mwangelwa
Cantrell, Ronald A.
Chintu, Namwinga
Stringer, Elizabeth M.
Chi, Benjamin H.
Sinkala, Moses
Kankasa, Chipepo
Wilson, Craig M.
Wilfert, Catherine M.
Mwango, Albert
Levy, Jens
Abrams, Elaine J.
Bulterys, Marc
Stringer, Jeffrey S. A.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (16): : 1888 - 1899
[5] PREVENTIVE THERAPY OF TUBERCULOSIS WITH RIFAPENTINE IN IMMUNOCOMPETENT AND NUDE-MICE
CHAPUIS, L
JI, BH
TRUFFOTPERNOT, C
OBRIEN, RJ
RAVIGLIONE, MC
GROSSET, JH
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 150 (05) : 1355 - 1362
[6] La cuerda dulce - a tolerability and acceptability study of a novel approach to specimen collection for diagnosis of paediatric pulmonary tuberculosis
Chow, Felicia
Espiritu, Nora
Gilman, Robert H.
Gutierrez, Rosmery
Lopez, Sonia
Escombe, A. Roderick
Evans, Carlton A. W.
Moore, David A. J.
[J]. BMC INFECTIOUS DISEASES, 2006, 6 (1)
[7] Donald PR, 2007, INT J TUBERC LUNG D, V11, P1162
[8] European Medicines Agency, 2007, EU PAED REG
[9] Effectiveness of antiretroviral treatment in a South African program - A cohort study
Fairall, Lara R.
Bachmann, Max O.
Louwagie, Goedele M. C.
van Vuuren, Cloete
Chikobvu, Perpetual
Steyn, Dewald
Staniland, Gillian H.
Timmerman, Venessa
Msimanga, Mpumelelo
Seebregts, Chris J.
Boulle, Andrew
Nhiwatiwa, Ralph
Bateman, Eric D.
Zwarenstein, Merrick F.
Chapman, Ronald D.
[J]. ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (01) : 86 - 93
[10] FEUER C, 2007, TUBERCULOSIS RES DEV

← 1 2 3 4 5 →